Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103 USD | +0.79% | -0.80% | +2.16% |
May. 02 | Leerink Partners Adjusts Cardinal Health Price Target to $120 From $118 | MT |
May. 02 | Transcript : Cardinal Health, Inc., Q3 2024 Earnings Call, May 02, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.11 for the 2024 fiscal year.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.16% | 24.85B | C+ | ||
+14.53% | 69.79B | C+ | ||
+7.11% | 8.2B | B | ||
-20.55% | 7.96B | B- | ||
-4.25% | 7.91B | C | ||
+2.32% | 4.69B | B- | ||
+17.12% | 4.32B | B+ | ||
-1.24% | 3.99B | B- | ||
-3.78% | 3.81B | B | ||
+21.42% | 3.62B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAH Stock
- Ratings Cardinal Health, Inc.